FAQ

Teceleukin

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

1989-2011
01219892011

Related topics

Related topics

6 relations
Cytokine Receptor ActivationGene Expression RegulationInhibition of Cell ProliferationInterleukin 2 Receptor
(More)

Related mentions per year

Related mentions per year

1938-2018
19401960198020002020
Teceleukin
Gene Expression Regulation
Lymphocyte Activation
Interleukin 2 Receptor
Inhibition of Cell Proliferation
immunopotentiation

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2011
2011
Phase I/II study of adoptive transfer of γδ T cells in combination with zoledronic acid and IL-2 to patients with advanced renal cell carcinoma
Human Vγ2 Vδ2-bearing T cells have recently received much attention in cancer immunotherapy. In this study, we conducted a phase… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
Highly Cited
2006
Highly Cited
2006
Safety profile and anti-tumor effects of adoptive immunotherapy using gamma-delta T cells against advanced renal cell carcinoma: a pilot study
Although various types of immunotherapy have been used to improve the prognosis of patients with advanced renal cell carcinoma… (More)
  • table 1
  • table 2
  • table 3
  • table 4
  • figure 1
Is this relevant?
2004
2004
A low-dose combination therapy of IL-2 and IFNα for metastatic renal cell cancer.
  • Hisaaki Akaza
  • Journal of clinical oncology : official journal…
  • 2004
4670 Background: In Japan, the officially recommended dose of interleukin-2 (IL-2) is low as less than one tenth of that in U.S.A… (More)
Is this relevant?
Review
1993
Review
1993
Interleukin-2. A review of its pharmacological properties and therapeutic use in patients with cancer.
Recombinant interleukin-2 (IL-2) products (e.g. aldesleukin, teceleukin) are nonglycosylated, modified forms of the endogenous… (More)
  • table I
  • table II
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
1991
1991
A phase II trial of interleukin-2 by continuous infusion and interferon by intramuscular injection in patients with renal cell carcinoma.
Fifteen patients with advanced, measurable renal cell carcinoma entered a Phase II clinical trial of interleukin-2 (IL-2… (More)
Is this relevant?
Review
1991
Review
1991
Recombinant interleukin-2: a biological response modifier.
The chemical properties, pharmacology, immunology, pharmacokinetics, clinical trials, adverse effects, and dosage and… (More)
Is this relevant?
1989
1989
Pharmacokinetics of teceleukin (recombinant human interleukin-2) after intravenous or subcutaneous administration to patients with cancer.
Single doses of teceleukin ranging from 0.1 to 30 x 10(6) units were administered to cancer patients as intravenous infusions or… (More)
Is this relevant?